Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isoleucine-tryptophan dipeptide is a synthetic or naturally derived peptide composed of the amino acids isoleucine and tryptophan. It has been studied for its antihypertensive and cardioprotective effects. Mechanistically, it acts as a potent inhibitor of angiotensin-converting enzyme (ACE), with an in vitro IC50 of 0.7 μM. In animal models (spontaneously hypertensive rats), administration of this dipeptide significantly reduced systolic blood pressure and myocardial mass compared to controls. It also blunted tissue ACE activity, reduced matrix metalloproteinase-2 activity (MMP-2), improved coronary flow reserve, and decreased plasma ACE activity. These effects suggest potential utility as a functional food additive or nutraceutical for attenuating hypertension and providing cardiovascular protection[1][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isoleucine-tryptophan dipeptide.